Clinical trials: Primary Parkinsonism
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Sialorrhea Secondary to Parkinson's Disease
Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
The primary goal of the study is to evaluate the safety and potential efficacy of intra-oral dissolvable NH004 films to improve the short-term symptoms of sialorrhea (drooling) in Parkinson's disease (PD) patients.
- Trial name
- NH004-2 (NCT00761137)
- Testing
- 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
- Where
- Argentina
- Volunteers
- 19 people
- Sponsor
- NeuroHealing Pharmaceuticals Inc.
Parkinson's Disease
A Pilot Study of Oxaloacetate in Subjects With Treated PD
The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4…
- Trial name
- NCT01741701
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Parkinson's Disease
Parkinson's Disease Isradipine Safety Study
The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD.
- Trial name
- NCT00753636
- Testing
- Dynacirc CR (Isradipine)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa Decarboxylase Inhibitor (DDCI), in patients with…
- Trial name
- NCT01568073
- Testing
- BIA 9-1067, Entacapone, Levodopa
- Where
- Portugal
- Volunteers
- 600 people
- Sponsor
- Bial - Portela C S.A.
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson's Disease
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple sclerosis.
- Trial name
- NCT01491022
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Parkinson Disease
Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
This single-center, randomized, quadruple-blinded, double-crossover comparative efficacy trial will study the effects of unilateral 50% voltage reduction in axial motor dysfunction for patients with Parkinson's disease that…
- Trial name
- NCT03462082
- Testing
- Asymmetric STN-DBS
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Toronto
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems.
- Trial name
- NCT00988117
- Testing
- Rivastigmine Patch 9.5 cm2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Parkinson Disease, Parkinson Disease Dementia
Sing for Your Saunter - Dementia Supplement
Older adults, and particularly those with Parkinson disease (PD), may experience walking difficulties that negatively impact their daily function and quality of life.
- Trial name
- SFYS-D (NCT04518917)
- Testing
- Mentally Singing, Listening to music
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Parkinson's Disease
Feasibility and Acceptability of a Physical Activity Behavior Change Intervention for Parkinson's Disease
The purpose of this study is to assess the feasibility, in regards to acceptability and implementation, of the Pre-Active PD intervention for increased high intensity goal-directed aerobic exercise engagement in people with…
- Trial name
- Preactive-PD (NCT03696589)
- Testing
- Physical Activity Coaching
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Teachers College, Columbia University
Parkinson Disease, Orthostatic Hypotension
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Levodopa is a precursor of dopamine and is the treatment of choice to treat the motor symptoms of Parkinson's disease (PD); however, the effect of levodopa on cardiovascular autonomic function in PD is poorly understood.
- Trial name
- NCT05487300
- Testing
- Autonomic testing on and off levodopa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Parkinson's Disease, Hyperprolactinemia
Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline. Specific objectives will be to assess: 1.
- Trial name
- SUCRE (NCT01270711)
- Testing
- Study Drug
- Volunteers
- 22,014 people
- Sponsor
- Pfizer
Parkinson Disease
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- NCT04995081
- Testing
- Biological/Vaccine: Allogeneic HB-adMSCs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hope Biosciences Research Foundation
Parkinson's Disease
Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease
The research team used meta-analytical statistical methods to integrate the results of different research groups on Parkinson's disease, using meta-analysis to find key genes related to the pathogenesis and development of…
- Trial name
- NCT03848455
- Testing
- genetic diagnosis
- Where
- China
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Parkinson's Disease
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease…
- Trial name
- PASADENA (NCT03100149)
- Testing
- RO7046015
- Where
- 55 sites in United States, Austria and 3 more
- Volunteers
- 316 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Pioglitazone in Early Parkinson's Disease
This is a multi-center, double-blind, placebo controlled clinical trial of two dosages of oral pioglitazone (15 milligram(mg) and 45 milligram (mg)) for safety, tolerability, and futility.
- Trial name
- NCT01280123
- Testing
- Pioglitazone
- Where
- 38 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Rochester
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma